Table 1 TCGA liver cancer patient characteristics.
From: ADAM12 is an independent predictor of poor prognosis in liver cancer
Characteristic | Low expression of ADAM12 | High expression of ADAM12 | p |
|---|---|---|---|
n | 187 | 187 | Â |
T stage, n (%) | Â | Â | 0.007 |
T1 | 107 (28.8%) | 76 (20.5%) | Â |
T2 | 42 (11.3%) | 53 (14.3%) | Â |
T3 | 34 (9.2%) | 46 (12.4%) | Â |
T4 | 3 (0.8%) | 10 (2.7%) | Â |
N stage, n (%) | Â | Â | 0.354 |
N0 | 133 (51.6%) | 121 (46.9%) | Â |
N1 | 1 (0.4%) | 3 (1.2%) | Â |
M stage, n (%) | Â | Â | 1.000 |
M0 | 139 (51.1%) | 129 (47.4%) | Â |
M1 | 2 (0.7%) | 2 (0.7%) | Â |
Pathologic stage, n (%) | Â | Â | 0.021 |
Stage I | 103 (29.4%) | 70 (20%) | Â |
Stage II | 39 (11.1%) | 48 (13.7%) | Â |
Stage III | 36 (10.3%) | 49 (14%) | Â |
Stage IV | 2 (0.6%) | 3 (0.9%) | Â |
Gender, n (%) | Â | Â | 0.047 |
Female | 51 (13.6%) | 70 (18.7%) | Â |
Male | 136 (36.4%) | 117 (31.3%) | Â |
Age, n (%) | Â | Â | 0.196 |
≤ 60 | 82 (22%) | 95 (25.5%) |  |
> 60 | 105 (28.2%) | 91 (24.4%) |  |
Residual tumour, n (%) | Â | Â | 0.023 |
R0 | 174 (50.4%) | 153 (44.3%) | Â |
R1 | 4 (1.2%) | 13 (3.8%) | Â |
R2 | 1 (0.3%) | 0 (0%) | Â |
Histological grade, n (%) | Â | Â | 0.173 |
G1 | 34 (9.2%) | 21 (5.7%) | Â |
G2 | 89 (24.1%) | 89 (24.1%) | Â |
G3 | 55 (14.9%) | 69 (18.7%) | Â |
G4 | 7 (1.9%) | 5 (1.4%) | Â |
Vascular invasion, n (%) | Â | Â | 0.276 |
No | 115 (36.2%) | 93 (29.2%) | Â |
Yes | 53 (16.7%) | 57 (17.9%) | Â |
OS event, n (%) | Â | Â | 0.013 |
Alive | 134 (35.8%) | 110 (29.4%) | Â |
Dead | 53 (14.2%) | 77 (20.6%) | Â |
DSS event, n (%) | Â | Â | 0.019 |
Alive | 154 (42.1%) | 133 (36.3%) | Â |
Dead | 30 (8.2%) | 49 (13.4%) | Â |
